Latest by Terri Wilder, M.S.W.
A poster presentation at the AIDS 2018 conference examined some of the challenges and barriers providers experience in screening and prescribing PrEP to their patients.
New information was presented at the 2018 International AIDS Conference in Amsterdam about babies born with neural tube defects to women with HIV who started a regimen with dolutegravir (Tivicay, DTG) and then later got pregnant.
Barr, a longtime AIDS activist and co-founder of Treatment Action Group (TAG), was the coordinator for the Joep Lange Institute's AIDS 2018 preconference workshop, Meeting the 90-90-90 Targets: Faster and Better.
Anthony Fauci Discusses Research Approaches to Sustaining HIV Remission Without Antiretroviral Therapy
Fauci spoke to TheBodyPRO at this year's International AIDS Conference on approaches to HIV remission and durable control of HIV without antiretroviral therapy.
At this year's AIDS 2018 in Amsterdam, Fauci detailed the scientific research that lead us on the path to the discovery that undetectable equals untransmittable (U=U).
Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.
Terri Wilder, M.S.W., spoke with John Schneider, M.D., M.P.H., author of a study that examined how accurate current guidelines for identifying PrEP candidates and risk-screening tools are among a group of young Black men who have sex with men.
Could a provider's personal beliefs about condom use affect their willingness to prescribe PrEP? One study surveyed U.S. medical students and found bias in terms of willingness to offer PrEP based on clinical situations.
One study in Amsterdam deployed a strategy to identify acute HIV in men who have sex with men (MSM) and then link newly diagnosed individuals to care.
One study set out to examine how effective opt-out testing for HIV and hepatitis C (HCV) could be among individuals who entered the Dallas County jail.